2 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DMEDiabetic Macular Edema (DME)Active, not recruitingPhase 2 / Phase 32026-09-30NCT06571045
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVOEmbolism and Thrombosis, Venous Thrombosis, cardiovascular disorder, eye disorder, retinal disorder, retinal vein occlusion, thrombotic disease, vascular disorderRecruitingPhase 22026-09-04NCT07205887